Ryvu Therapeutics Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Ryvu Therapeutics has a total shareholder equity of PLN205.4M and total debt of PLN60.5M, which brings its debt-to-equity ratio to 29.5%. Its total assets and total liabilities are PLN406.6M and PLN201.2M respectively.
Anahtar bilgiler
29.5%
Borç/özkaynak oranı
zł60.51m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | zł254.20m |
| Eşitlik | zł205.41m |
| Toplam yükümlülükler | zł201.24m |
| Toplam varlıklar | zł406.65m |
Son finansal sağlık güncellemeleri
Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt
Oct 20
We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate
Aug 02Recent updates
Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt
Oct 20We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate
Aug 02Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?
Jan 25What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?
Feb 05Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return
Dec 14Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: RVU's short term assets (PLN296.5M) exceed its short term liabilities (PLN89.2M).
Uzun Vadeli Yükümlülükler: RVU's short term assets (PLN296.5M) exceed its long term liabilities (PLN112.0M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: RVU has more cash than its total debt.
Borcun Azaltılması: RVU's debt to equity ratio has increased from 2.1% to 29.5% over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: RVU has sufficient cash runway for more than a year based on its current free cash flow.
Tahmini Nakit Akışı: RVU has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 5.5% each year.